Inmune Bio Stock Investor Sentiment

INMB Stock  USD 9.22  0.16  1.77%   
About 56% of all INmune Bio's investors are looking to take a long position. The analysis of the overall investor sentiment regarding INmune Bio suggests that some traders are interested. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
  
over three months ago at gurufocus.com         
INmune Bio Inc Q2 2024 Earnings Call Highlights Promising Advances Amid Rising Costs
Gurufocus Stories at Macroaxis
over three months ago at news.google.com         
Where are the Opportunities in - Stock Traders Daily
Google News at Macroaxis
over three months ago at thelincolnianonline.com         
David J. Moss Acquires 10,000 Shares of INmune Bio, Inc. Stock
news
over three months ago at investing.com         
Inmune Bio CFO buys 52,868 in company stock
Investing News at Macroaxis
over three months ago at gurufocus.com         
Acquisition by Moss David J of 10000 shares of INmune Bio at 5.2868 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Insider Buying CFO and 10 percent Owner David Moss Acquires Shares of INmune Bio Inc
Gurufocus Stories at Macroaxis
over three months ago at finance.yahoo.com         
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimers Disease
Yahoo News
over three months ago at news.google.com         
Acquisition by Moss David J of 70663 shares of INmune Bio subject to Rule 16b-3
Google News at Macroaxis
over three months ago at news.google.com         
Achieve, INmune, Lenz stocks win bullish view from RayJay - Seeking Alpha
Google News at Macroaxis
over three months ago at globenewswire.com         
INKmune Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
Macroaxis News: globenewswire.com
over three months ago at finance.yahoo.com         
INKmune Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
Yahoo News
over three months ago at www.macroaxis.com         
Acquisition by Moss David J of 18028 shares of INmune Bio at 9.152 subject to Rule 16b-3
Macroaxis News
over three months ago at simplywall.st         
Raymond Tesi Buys Handful Of Shares In INmune Bio
Simply Wall St News at Macroaxis
over three months ago at news.google.com         
INmune Bio stock remains a Buy with positive data correlation in Alzheimers study, says Scotiabank -...
Google News at Macroaxis
over three months ago at investing.com         
Inmune Bio CEO acquires 98k in company stock
Investing News at Macroaxis
Far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. That information is available publicly through INmune media outlets and privately through word of mouth or via INmune internal channels. However, regardless of the origin, that massive amount of INmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.

INmune Bio Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account